Importantly, none of these clinical trials were adequately powered, well-designed, or replicated to confirm the efficacy of these interventions conclusively
Changes in vision: Semaglutide can cause vision changes and worsen diabetic retinopathy
You need to create the deficit through diet
Stubborn acne scars? Not anymore
Rates were higher than previously reported for GLP-1 mono agonists (semaglutide) and dual agonists (tirzepatide), which is consistent with a stronger overall incretin load
As a consequence, SELECT has raised the evidence threshold that innovators must clear when targeting conditions such as hypertension, dyslipidaemia or heart failure, including the effect size they need to demonstrate to be clinically meaningful and patient relevant